维生素D对心力衰竭患者全因死亡率的影响:EVITA试验
EVITA试验将400例25OHD<75 nmol/L的晚期心衰患者随机分配至每日4000 IU维生素D或安慰剂组治疗3年。维生素D组与安慰剂组全因死亡率无显著差异(19.6% vs 17.9%,HR 1.09,95%CI 0.69-1.71,P=0.726),但维生素D组机械循环支持植入需求更高(15.4% vs 9.0%,HR 1.96,95%CI 1.04-3.66,P=0.031)。
要点
- 每日4000 IU维生素D未降低晚期心衰患者全因死亡率。
- 维生素D组机械循环支持植入需求高于安慰剂组(HR 1.96)。
- 数据提示对长期补充中等高剂量维生素D需谨慎。
核心结论
- 每日4000 IU维生素D未降低晚期心衰患者死亡率,但与机械循环支持植入需求增加相关。
- 数据表明对长期补充中等高剂量维生素D需谨慎。
研究设计与样本
- 随机、安慰剂对照临床试验,纳入400例25OHD<75 nmol/L的晚期心衰患者。
- 患者随机接受每日4000 IU维生素D或匹配安慰剂治疗3年。
- 主要终点为全因死亡率。
主要发现
- 维生素D组全因死亡率19.6%(n=39)vs 安慰剂组17.9%(n=36),HR 1.09(95%CI 0.69-1.71;P=0.726)。
- 维生素D组机械循环支持植入需求15.4%(n=28)vs 安慰剂组9.0%(n=15),HR 1.96(95%CI 1.04-3.66;P=0.031)。
- 高钙血症发生率维生素D组6.2%(n=10)vs 安慰剂组3.1%(n=5),P=0.192。
- 其他次要临床终点两组间相似。
- 初始25OHD平均水平<40 nmol/L,安慰剂组维持约40 nmol/L,维生素D组平台约100 nmol/L。
临床怎么用
- 对于晚期心衰患者,每日4000 IU维生素D补充未显示降低死亡率的获益。
- 长期补充中等高剂量维生素D可能与机械循环支持植入需求增加相关,数据提示需谨慎。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Circulating 25-hydroxyvitamin D (25OHD) levels <75 nmol/L are associated with a nonlinear increase in mortality risk. Such 25OHD levels are common in heart failure (HF). We therefore examined whether oral vitamin D supplementation reduces mortality in patients with advanced HF. METHODS AND RESULTS: Four hundred HF patients with 25OHD levels <75 nmol/L were randomized to receive 4000 IU vitamin D daily or matching placebo for 3 years. Primary endpoint was all-cause mortality. Key secondary outcome measures included hospitalization, resuscitation, mechanical circulatory support (MCS) implant, high urgent listing for heart transplantation, heart transplantation, and hypercalcaemia. Initial 25OHD levels were on average <40 nmol/L, remained around 40 nmol/L in patients assigned to placebo and plateaued around 100 nmol/L in patients assigned to vitamin D. Mortality was not different in patients receiving vitamin D (19.6%; n = 39) or placebo (17.9%; n = 36) with a hazard ratio (HR) of 1.09 [95% confidence interval (CI): 0.69-1.71; P = 0.726]. The need for MCS implant was however greater in patients assigned to vitamin D (15.4%, n = 28) vs. placebo [9.0%, n = 15; HR: 1.96 (95% CI: 1.04-3.66); P = 0.031]. Other secondary clinical endpoints were similar between groups. The incidence of hypercalcaemia was 6.2% (n = 10) and 3.1% (n = 5) in patients receiving vitamin D or placebo (P = 0.192). CONCLUSION: A daily vitamin D dose of 4000 IU did not reduce mortality in patients with advanced HF but was associated with a greater need for MCS implants. Data indicate caution regarding long-term supplementation with moderately high vitamin D doses. TRIAL REGISTRATION INFORMATION: clinicaltrials.gov Idenitfier: NCT01326650.
引用
- Zittermann A, Ernst JB, Prokop S, et al. Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily. Eur Heart J. 2017. PMID: 28498942. doi:10.1093/eurheartj/ehx235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。